# CytoAgents

Source: https://onco.cc/companies/cytoagents/  
OnCo record `cytoagents` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CytoAgents is a Pittsburgh company developing CTO1681, a tablet meant to prevent cytokine release syndrome, a dangerous immune over-reaction that can follow CAR-T cell therapy. It is being tested in an early trial.

## Summary

CytoAgents, Inc., based in Pittsburgh, says it was founded in 2018 with a focus on cytokine release syndrome (CRS). Its compound CTO1681 is described by the company as an orally available, steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation; the website now also lists pulmonary arterial hypertension, asthma, atopic dermatitis and inflammation in the tumour microenvironment as indications. CytoAgents sponsors NCT05905328, a phase 1/2 trial of CTO1681 for the prevention and treatment of CRS in patients receiving CAR T-cell therapy, which ClinicalTrials.gov lists as recruiting. A 2026 National Cancer Institute SBIR award funds work on CTO1681 to prevent and mitigate CRS in people with multiple myeloma receiving CAR T-cell therapy.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: CytoAgents, Inc.
- HQ: Pittsburgh, PA
- Type: biotech
- Website: https://cytoagents.com/

## Notes

- Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05905328 read on 4 November 2026. NCT05905328 is not yet a trial record in OnCo.

## Sources

- Official website: https://cytoagents.com/
- NIH RePORTER: award 5R44CA295189-02: https://reporter.nih.gov/project-details/11418976
- ClinicalTrials.gov: CTO1681 for CRS after CAR T-cell therapy (NCT05905328): https://clinicaltrials.gov/study/NCT05905328

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [CTO1681](https://onco.cc/drugs/cto1681/)

---
JSON: https://onco.cc/api/v1/entities/cytoagents.json